GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Rapid Therapeutic Science Laboratories RTSL · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

—

FY2014FY2024

Net income

−$183,296

FY2014FY2024

Free cash flow

—

FY2014FY2024

Shareholders' equity

−$3.1m

FY2014FY2024

Income statement

Fiscal years

FY2024FY2022FY2021FY2019FY2018FY2017FY2016FY2015FY2014
Revenue——$534$9,139—————
Operating income−$83,226−$1.3m−$2.2m−$169,690−$152,075−$21,616−$12,020−$12,303−$18,957
Net income−$183,296−$1.7m−$4.2m−$348,841−$2.6m−$21,616−$12,020−$12,303−$18,957
Diluted earnings per share-0.01-0.22-0.55-0.11-52.97-0.20-0.11-0.11-0.17

Balance sheet

At each fiscal year end

FY2024FY2022FY2021FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$967,763$2.3m$2.2m$444,588$26,242$7,395$9,988$9,988$23,034
Cash and short-term investments—−$378,744$192,484$136,215$12,297$7,395$9,238$9,238$18,557
Total liabilities$4.1m$5.4m$3.6m$1.8m$2.9m$30,300$11,277$11,277−$23,034
Debt$3.4m$3.8m$2.0m$1.2m$2.8m$30,000$10,000$10,000—
Shareholders' equity−$3.1m−$3.1m−$1.4m−$1.4m−$2.9m−$22,905−$1,289−$1,289$23,034
Shares outstanding19m8m8m3m0m0m0m0m0m

Cash flow

Fiscal years

FY2024FY2022FY2021FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations—−$1.2m−$2.2m−$106,663−$129,854−$21,843−$10,743−$10,743−$13,434
Capital spending—−$39,155−$292,531−$155,075−$38,620−$38,620−$38,620——
Free cash flow—−$1.2m−$2.5m−$261,738−$168,474−$60,463−$49,363−$10,743−$13,434

Latest quarters

By quarter end

Dec 2024Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021
Revenue———————$60
Operating income−$9,384−$21,203−$98,294$27,342−$372,907−$128,375−$789,393−$560,490
Net income−$34,538$46,422$591,862$30,768−$573,247−$802,428−$2.3m−$1.2m
Diluted earnings per share-0.000.010.070.00-0.07-0.10-0.30-0.16
Total assets$967,763$2.1m$2.0m$2.3m$2.3m$2.4m$2.7m$2.2m
Cash and short-term investments—$2,160$17,572−$378,744−$397,410$112,164$32,985$192,484
Debt$3.4m$3.5m$3.5m$3.6m$3.5m$3.2m$2.9m$1.6m
Shareholders' equity−$3.1m−$2.7m−$2.8m−$3.1m−$3.1m−$2.9m−$2.9m−$1.4m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income—-11.4%15.3%
Net income—-40.9%24.8%

Valuation history

At each fiscal year end

FY2024FY2021
Price to earnings-0.1—
Price to sales—1.2

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return425%826%-55%-29%-60%2021%-23%47%497%8%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 25-to-1 reverse split · 31 Mar 2022

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.